Eyeing a hot IPO market, 4DMT tops up its cash reserves and preps a leap into the clinic with bespoke gene therapy vectors
It took 4D Molecular Therapeutics 7 years to build its gene therapy vector platform, line up a marquee industry deal and prep a string of INDs. And now it has the money to fund the next big stage as the team plans a near-term launch of their first clinical studies to test its custom-built gene therapies in humans.
The 80-person 4DMT team led by CEO David Kirn put out word Tuesday morning that they have landed a $75 million C round to keep the work on track.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,800+ biopharma pros reading Endpoints daily — and it's free.